PDI, Inc. (Nasdaq: PDII) recently announced that its molecular diagnostics subsidiary, Interpace Diagnostics, has launched its new next-generation sequencing (NGS) ThyGenX™ test to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules. Over 525,000 thyroid FNA’s (fine needle aspirates) are performed annually and up to 30% of the results are indeterminate. ThyGenX is used to improve risk stratification to help minimize the need for unnecessary surgical procedures when standard cytopathology does not provide a clear diagnosis of thyroid cancer.
PDI, Inc. Subsidiary Interpace Diagnostics Announces Launch of ThyGenX Next-Generation Sequencing (NGS) Test for Cancer Risk Assessment of Thyroid Nodules
Castle Biosciences Inc., a leading developer of diagnostic and prognostic tests for rare cancers, recently announced the launch of an educational program dedicated to the information needs of Stage I and II skin (cutaneous) melanoma patients and their caregivers. The program kicks off with the launch of an animated video, ” Predicting Risk in Early Stage Melanoma ” that describes how physicians stage melanoma cancers, and how the availability of a new genomic test can further clarify an individual’s risk of the cancer returning.
Critical Diagnostics recently announced the release of a paper titled, “Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator),” published on PLOS ONE, an open-access resource from the Public Library of Science, that introduces a powerful new free online risk calculator designed to help health care professionals better manage patients with heart failure.
PAM50-Based Prosigna Breast Cancer Assay Helps to Identify Patients at Risk of Late Distant Recurrence in a Combined Analysis of 2,137 Patients
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, recently announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment. Using the Prosigna Assay, the study investigators classified patient tumors by subtype and found that patients with Luminal B subtype have three times higher risk of late distant recurrence than patients with Luminal A subtype tumors. Results were presented at the 2013 San Antonio Breast Cancer Symposium.
Although Parkinson’s disease is the second most prevalent neurodegenerative disorder in the U.S., there are no standard clinical tests available to identify this widespread condition. As a result, Parkinson’s disease often goes unrecognized until late in its progression, when the brain’s affected neurons have already been destroyed and telltale motor symptoms such as tremor and rigidity have already appeared.